Shennon Biotechnologies Developed Tumor Therapy Platform
The San Francisco-based firm created a microfluidics system originating from research conducted at Harvard University.
Updated on Sept. 23, 2026 in Biotech
Live Poll
Is medical research making solid tumor treatments more effective for patients?
Founded in 2021, Shennon Biotechnologies Inc. established a proprietary microfluidics platform designed to accelerate solid tumor therapy discovery. The system utilizes advanced fluorescent droplet sorting to screen immune activity and single-cell interactions.
Why it matters
The platform aims to address major challenges in oncology, specifically tumor heterogeneity and antigen escape, by facilitating the development of complex therapeutic candidates.
The Tcelerator system employs microfluidic chips to encapsulate individual cell pairs within droplets for high-throughput screening. This technical approach allows for the precise analysis of immune activity against target tumor cells.
The players
Shennon Biotechnologies Inc.
A biotechnology company headquartered in San Francisco that focuses on discovering therapies for solid tumors.
Li Sun
The founder who established Shennon Biotechnologies Inc. in 2021.
Harvard University
The academic institution where the research behind the microfluidics platform technology originated.
The details
The technology, which emerged from research at Harvard University, allows researchers to observe interactions between immune cells and tumor cells at a single-cell level. By encapsulating these pairs in fluid channels, the system isolates specific interactions for detailed study and therapeutic selection.
Timeline
Shennon Biotechnologies Inc. was founded in 2021.
The Tech Race
The integration of microfluidics into cancer research represents a move away from traditional bulk-cell analysis toward high-resolution single-cell screening. This positions Shennon Biotechnologies alongside other innovators utilizing fluid dynamics to solve complex immunological challenges.
While the technology is currently focused on early-stage discovery, the platform may eventually reduce the time required to bring novel cancer treatments to clinical testing. These advancements represent a long-term improvement in the tools available for tackling resistant solid tumors.
The takeaway
The use of microfluidics for single-cell interaction screening highlights how academic research is increasingly driving pharmaceutical innovation. This approach demonstrates a commitment to solving difficult biological problems through high-precision engineering.
Further reading
For more information on recent advancements in this field, visit Biotech.
Source note: This article includes information reported by BioCentury.
Live Poll
Is medical research making solid tumor treatments more effective for patients?
